Business
NeuroSense Therapeutics Granted Patent in Canada for its ALS Drug PrimeC
- Patent valid through 2038 - Phase IIb ALS trial expected to commence H1 2022 CAMBRIDGE, Mass., April 6, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
About this update from Neurosense Therapeutics Ltd.
[{"type":"text","content":"- Patent valid through 2038\n- Phase IIb ALS trial expected to commence H1 2022\n CAMBRIDGE, Mass., April 6, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (\"NeuroSense\"), a company developing treatments for severe neurodegenerative diseases, today announced the Canadian Intellectual Property Office has granted the Company a key patent titled \"Compositions comprising an anti-inflammatory drug and DICER activator for treatment of neuronal diseases\" having the number 3,068,149. The patent covers NeuroSense's unique fixed-dose combination of ciprofloxacin and celecoxib, two US FDA-approved drugs that are the active ingredients in PrimeC, the Company's lead drug candidate for treating Amyotrophic Lateral Sclerosis (\"ALS\"). This patent has already been issued in the U.S. and Australia and is valid through 2038, subject to appropriate maintenance and renewal. The Company also received a patent allowance from the European Patent Office, and similar patent applications are pending in Japan and Israel. Additional patent applications relating to the novel formulation of PrimeC and methods for the treatment of other neurodegenerative diseases using NeuroSense's platform of combination therapies including StabiliC and CogniC are pending as well.\n\n \n \n \n \n \n \n\n \nNeuroSense's PrimeC ALS program is headed into two clinical trials, a pharmacokinetic study to be conducted under an FDA IND which is slated to commence in the next few weeks, and a Phase IIb double-blind placebo controlled multinational study to commence Q2 2022. The Phase IIb study with PrimeC's unique formulation is expected to demonstrate results that may be superior to those already achieved in a previous Phase IIa study that met its endpoints. Concurrently, NeuroSense is investigating ALS biomarkers in conjunction with Massachusetts General Hospital with the aim of increasing the success in a future pivotal clinical study. Data from the Mass General biomarker study is expected Q2 2022. \n\"We are pleased to receive this most recent patent grant which adds to our growing IP portfolio at this important junction as we head into a Phase IIb study. ALS is an indication in dire need of an effective treatment, and we are determined to advance our program, backed by strong IP, toward market, fulfilling our commitment to people with ALS,\" stated Alon B...